US equities |
MU $1,043.81 ▼-2.00% NVDA $229.67 ▲+0.57% SNDK $1,727.71 ▼-0.70% AMD $608.28 ▼-0.57% INTC $119.27 ▼-0.80% GOOGL $340.47 ▼-1.05% TSLA $358.09 ▲+0.92% MSFT $513.67 ▲+0.15%
FinancialContent Watchlist

Articles published by SinoMab BioScience Limited

News headline image
Dr. Shui On Leung Invited to the 2026 LifeArc Translational Science Summit in the UK
From SinoMab BioScience Limited
Via ACN Newswire
News headline image
SinoMab (03681.HK) Achieves Approximately 43.3% Year-over-Year Decrease in Annual Losses for 2025, Marking Significant Progress in Pipeline Advancement
From SinoMab BioScience Limited
Via ACN Newswire
News headline image
SinoMab BioScience Limited Breakthrough Phase 1b POC Results for SM17 in Atopic Dermatitis
From SinoMab BioScience Limited
Via ACN Newswire
News headline image
SinoMab Awarded the "Most Valuable Pharmaceutical and Medical Company" in the Selection of the "7th Hong Kong Golden Stocks Awards"
From SinoMab BioScience Limited
Via ACN Newswire
News headline image
IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Approved by FDA
From SinoMab BioScience Limited
Via ACN Newswire
News headline image
IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Accepted by FDA
From SinoMab BioScience Limited
Via ACN Newswire
News headline image
SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE
From SinoMab BioScience Limited
Via ACN Newswire
News headline image
SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03
From SinoMab BioScience Limited
Via ACN Newswire
News headline image
SinoMab Was Invited to Attend the Inaugural Asia Summit on Global Health
From SinoMab BioScience Limited
Via ACN Newswire
News headline image
SinoMab, Sinovent and Everest Medicines Announce Licensing Agreement for Global Development and Commercialization of A Next-Generation BTK Inhibitor in Renal Diseases
From SinoMab BioScience Limited
Via ACN Newswire
News headline image
SinoMab Awared the "Best Small and Mid-Cap Company" and "Best CEO" in the Selection of the "6th Hong Kong Golden Stocks Awards" and the "Listed Company with the Most Growth Potential" in the Selection of "2021 Sina Finance Golden Unicorn Best Hong Kong
From SinoMab BioScience Limited
Via ACN Newswire